loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Lisaftoclax

    Client Email Product
    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Menu

    Lisaftoclax

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascentage Releases Lisaftoclax Data At EHA Showing Improvement In Amyloidosis
    Ascentage Releases Lisaftoclax Data At EHA Showing Improvement In Amyloidosis

    18 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-eha-2024--ascentage-pharma-releases-updated-data-of-lisaftoclax-in-patients-with-rr-mm-and-al-amyloidosis-highlighting-marked-improvement-in-orr-302175033.html

    PR NEWSWIRE
    18 Jun 2024
    Share Share
    Ascentage Pharma: Lisaftoclax Safety/Efficacy Data In Waldenstrom's Cancer
    Ascentage Pharma: Lisaftoclax Safety/Efficacy Data In Waldenstrom's Cancer

    04 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-asco-2024--ascentage-pharma-releases-updated-data-showing-promising-efficacy-and-safety-of-lisaftoclax-in-patients-with-wm-302164161.html

    PR NEWSWIRE
    04 Jun 2024
    Share Share
    Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax
    Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax

    11 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2023--ascentage-pharma-presents-the-first-dataset-of-bcl-2-inhibitor-lisaftoclax-in-patients-with-aml-demonstrating-favorable-efficacy-and-safety-302011941.html

    PR NEWSWIRE
    11 Dec 2023
    Share Share
    Ascentage Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax
    Ascentage Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax

    11 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2023--ascentage-pharma-releases-encouraging-long-term-data-of-bcl-2-inhibitor-lisaftoclax-in-rr-cll-including-an-orr-of-73-3-302010995.html

    PR NEWSWIRE
    11 Dec 2023
    Share Share
    Ascentage to Present Results from Three Studies of Bcl-2 Inhibitor Lisaftoclax
    Ascentage to Present Results from Three Studies of Bcl-2 Inhibitor Lisaftoclax

    02 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ash-2023--ascentage-pharma-to-present-results-from-three-clinical-studies-of-bcl-2-inhibitor-lisaftoclax-apg-2575-including-the-first-data-in-aml-and-mm-301976616.html

    PR NEWSWIRE
    02 Nov 2023
    Share Share
    Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration
    Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration

    15 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascentage-pharma-and-astrazeneca-enter-into-clinical-collaboration-on-the-registrational-phase-iii-study-of-bcl-2-inhibitor-lisaftoclax-in-combination-with-btk-inhibitor-acalabrutinib-in-treatment-naive-patients-with-first-line-cl-301956934.html

    PR NEWSWIRE
    15 Oct 2023
    Share Share